{"brief_title": "A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive Patients", "brief_summary": "This study evaluated two doses of tenofovir alafenamide versus tenofovir disoproxil fumarate (tenofovir DF).", "condition": "HIV Infections", "intervention_type": "Drug", "intervention_name": "Tenofovir alafenamide", "description": "Tenofovir alafenamide tablet(s) administered orally once daily", "arm_group_label": "Tenofovir alafenamide 150 mg", "other_name": "GS-7340", "criteria": "Inclusion Criteria - HIV-1 RNA levels greater than or equal to 30,000 copies/mL - CD4 count greater than or equal to 200 cells/mm3 - Serum creatinine <1.5 mg/dl - Hepatic transaminases less than or equal to 2.5 times the upper limit of normal - Total bilirubin less than or equal to 1.5 mg/dL - Adequate hematologic function - Serum amylase less than or equal to 1.5 times the upper limit of normal - Serum phosphate greater than or equal to 2.2 mg/dL - Not pregnant Exclusion Criteria - Prior treatment with antiretroviral therapy - Immunization within 30 days of study entry - A new AIDS defining condition within 30 days of study entry - Receiving nephrotoxic agents, probenecid, chemotherapeutic agents, corticosteroids, interleukin-2", "gender": "All", "minimum_age": "18 Years", "maximum_age": "65 Years", "healthy_volunteers": "No", "id": "NCT00036634.xml"}